3rd feasibility agreement

Apidel signs a third feasibility study with a major player in dermatology for two new drug products using our ApidSOL™ technology.


2nd feasibility agreement

Apidel signs a feasibility agreement for a sustained-release formulation using ApidCOR™ with one of the largest pharmaceutical companies worldwide.


1st feasibility agreement

Apidel signs a feasibility agreement for a sustained-release formulation using ApidCOR™ with an international pharmaceutical company


Laboratory Opening

Apidel opens its own laboratory and appoints first staff.


Private Placement

Apidel completes a private placement to develop its technologies and start building its own portfolio of products.


Option & licence agreement

Apidel signs an option & licence agreement for a number of drugs to be associated with ApidSOL™ with an international pharmaceutical company.


ApidCOR & ApidSOL

Apidel is assigned exclusive worldwide rights by University of Geneva on ApidCOR & ApidSOL.


APIDEL Foundation

Apidel is created!